Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree - 2Manual for Purchasing a Modest Jeep Wrangler for Seniors
- 3When is MLK Day? Plus, the dates of when other federal holidays land in 2026.
- 4Reveal Less popular Authentic Realities You Didn't Learn in School
- 5The most effective method to Involve Handshakes for Compromise and Compromise
- Must-See Attractions in Washington, D.C.
- Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- BravoCon 2025: How to watch, full schedule and lineup, where to stream free and more
- The cheap health insurance promoted by Trump officials has this catch
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- Best Getaway destination: Ocean side, Mountain, or City
- How will the universe end?
- France will build a new aircraft carrier as it increases defense spending
- Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely
